Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1310-1319.doi: 10.12092/j.issn.1009-2501.2026.10.002
Qiujin JIA1(
), Lu FAN2, Haomin ZHANG2, Xiaoling WANG3, Xiaonan ZHANG2, Peng YUAN2, Yujie HAO3, Wenbao HAN3, Zhuo YUAN2, Yunjiao WANG2, Chao ZHAO4, Shichao LYU2,*(
)
Received:2025-07-03
Revised:2025-12-14
Online:2026-10-26
Published:2026-11-11
Contact:
Shichao LYU
E-mail:1261764461@qq.com;dr_lv@foxmail.com
CLC Number:
Qiujin JIA, Lu FAN, Haomin ZHANG, Xiaoling WANG, Xiaonan ZHANG, Peng YUAN, Yujie HAO, Wenbao HAN, Zhuo YUAN, Yunjiao WANG, Chao ZHAO, Shichao LYU. Study on the mechanism of Shenshao tablets based on heart-intestinal flora axis in the treatment of chronic heart failure[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1310-1319.
Fig.1 Effects of Shenshao tablets on cardiac function and ventricular structure in rats with chronic heart failure ($\bar x $±s, n=8) A: gross morphology of the heart; B: cardiac ultrasound; C: HE staining; D: Masson staining; E: left ventricular mass index; F: heart mass index; G: NT-proBNP; H: left ventricular end-systolic diameter; I: left ventricular end-diastolic diameter; J: left ventricular ejection fraction; K: myocardial collagen volume fraction; L: C-terminal telopeptide of type I collagen; M: N-terminal propeptide of type III procollagen; N: C-terminal propeptide of type I procollagen. #P<0.05, *P<0.01.
Fig.2 Effects of Shenshao tablets on intestinal barrier function in rats with chronic heart failure ($\bar x $±s, n=8) A: HE staining of ileal tissue; B: diamine oxidase; C: D-lactate; D: endotoxin. #P<0.05, *P<0.01.
Fig.3 Effects of Shenshao tablets on the alpha diversity of gut microbiota in rats with heart ($\bar x $±s, n=8) A: shannon index; B: rarefaction curve; C: Chao1 index; D: rank abundance curve. #P<0.05, *P<0.01.
Fig.4 Effects of Shenshao tablets on the beta diversity of gut microbiota in rats with heart failure ($\bar x $±s, n=8) A: heatmap of beta diversity indices; B: box plot based on unweighted unifrac beta diversity; C: box plot based on weighted unifrac beta diversity; D: PCA analysis. #P<0.05, *P<0.01.
Fig.5 Effects of Shenshao tablets on the structure of gut microbiota in rats with heart failure A: bar chart of the relative abundance of the top 10 species at the phylum level; B: heatmap of the relative abundance of the top 35 species at the genus level across groups; C: bar chart of the relative abundance of the top 10 species at the genus level.
Fig.6 Effects of Shenshao tablets on intestinal metabolites in rats with chronic heart failure A-B: Z-score plots of TMAO and its precursor levels; C-D: Z-score plots of SCFA levels.
| 1 | 中国老年医学学会心电与心功能分会, 中国心衰中心联盟专家委员会, 中华医学会《中华全科医师杂志》编辑委员会. 心力衰竭早期筛查与一级预防中国专家共识(2024年)[J]. 中华全科医师杂志, 2024, 23 (1): 7- 18. |
| 2 | 心血管健康联盟, 中国老年医学学会心电与心功能分会, 心衰中心联盟专家委员会. 中国心衰中心联盟心力衰竭医疗质量报告(2022年)[J]. 中华全科医师杂志, 2023, 22 (6): 557- 568. |
| 3 | Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145 (18): e895- e1032. |
| 4 | 刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》概要(心血管疾病流行及介入诊疗状况)[J]. 中国介入心脏病学杂志, 2024, 32 (10): 541- 550. |
| 5 |
Chen Y, Zhou J, Wang L. Role and mechanism of gut microbiota in human disease[J]. Front Cell Infect Microbiol, 2021, 11, 625913.
doi: 10.3389/fcimb.2021.625913 |
| 6 | Pasini E, Aquilani R, Testa C, et al. Pathogenic gut flora in patients with chronic heart failure[J]. JACC Heart Fail, 2016, 4 (3): 220- 227. |
| 7 | Nagatomo Y, Tang WH. Intersections between microbiome and heart failure: revisiting the gut hypothesis[J]. J Card Fail, 2015, 21 (12): 973- 980. |
| 8 | Sun H, Xing ZY, Huang JY, et al. Meta-analysis and trial sequential analysis of Shenshao Capsules in treatment of angina pectoris in coronary heart disease[J]. China J Chin Mater Med, 2024, 49 (12): 3385- 3395. |
| 9 | 刘云霏. 参芍片对冠心病合并心衰患者心功能及生活质量的影响[J]. 慢性病学杂志, 2020, 21 (2): 228- 229,232. |
| 10 | Xie B, Zu X, Wang Z, et al. Ginsenoside Rc ameliorated atherosclerosis via regulating gut microbiota and fecal metabolites[J]. Front Pharmacol, 2022, 13, 990476. |
| 11 | Yang X, Dong B, An L, et al. Ginsenoside Rb1 ameliorates glycemic disorder in mice with high fat diet-induced obesity via regulating gut microbiota and amino acid metabolism[J]. Front Pharmacol, 2021, 12, 756491. |
| 12 | Xu SY, Cao HY, Yang RH, et al. Genus Paeonia monoterpene glycosides: a systematic review on their pharmacological activities and molecular mechanisms[J]. Phytomedicine, 2024, 127, 155483. |
| 13 | Zhan Y, Wen Y, Zhang LL, et al. Paeoniflorin improved constipation in the loperamide-induced rat model via TGR5/TRPA1 signaling-mediated 5-Hydroxytryptamine secretion[J]. Evid Based Complement Alternat Med, 2021, 2021, 6076293. |
| 14 | Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China Heart Failure (China-HF) registry[J]. J Card Fail, 2017, 23 (12): 868- 875. |
| 15 | Stewart S, MacIntyre K, Hole DJ, et al. More "malignant" than cancer? Five-year survival following a first admission for heart failure[J]. Eur J Heart Fail, 2001, 3 (3): 315- 322. |
| 16 | Masenga SK, Povia JP, Lwiindi PC, et al. Recent advances in microbiota-associated metabolites in heart failure[J]. Biomedicines, 2023, 11 (8): 2313. |
| 17 | Dai H, Hou T, Wang Q, et al. Causal relationships between the gut microbiome, blood lipids, and heart failure: a Mendelian randomization analysis[J]. Eur J Prev Cardiol, 2023, 30 (12): 1274- 1282. |
| 18 | Schneider E, O'Riordan KJ, Clarke G, et al. Feeding gut microbes to nourish the brain: unravelling the diet-microbiota-gut-brain axis[J]. Nat Metab, 2024, 6 (8): 1454- 1478. |
| 19 | Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies[J]. Nutrients, 2022, 14 (13): 2654. |
| 20 | Shen S, Tian B, Zhang H, et al. Heart failure and gut microbiota: what is cause and effect?[J]. Research (Wash D C), 2025, 8, 0610. |
| 21 | Tang WHW, Lemaitre RN, Jensen PN, et al. Trimethylamine N-oxide and related gut microbe-derived metabolites and incident heart failure development in community-based populations[J]. Circ Heart Fail, 2024, 17 (8): e011569. |
| 22 | Yukino-Iwashita M, Nagatomo Y, Kawai A, et al. Short-chain fatty acids in gut-heart axis: their role in the pathology of heart failure[J]. J Pers Med, 2022, 12 (11): 1805. |
| 23 | Chulenbayeva L, Issilbayeva A, Sailybayeva A, et al. Short-chain fatty acids and their metabolic interactions in heart failure[J]. Biomedicines, 2025, 13 (2): 343. |
| 24 | Poland JC, Flynn CR. Bile acids, their receptors, and the gut microbiota[J]. Physiology (Bethesda), 2021, 36 (4): 235- 245. |
| 25 | Wan S, Cui Z, Wu L, et al. Ginsenoside Rd promotes omentin secretion in adipose through TBK1-AMPK to improve mitochondrial biogenesis via WNT5A/Ca2+ pathways in heart failure[J]. Redox Biol, 2023, 60, 102610. |
| 26 | Yu T, Xu X, Wei J, et al. Ginsenoside Rg5 alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the JNK/AP-1 pathway[J]. Int Immunopharmacol, 2023, 120, 110408. |
| 27 | Peng Y, Liao B, Zhou Y, et al. Ginsenoside Rb2 improves heart failure by down-regulating miR-216a-5p to promote autophagy and inhibit apoptosis and oxidative stress[J]. J Appl Biomed, 2023, 21 (4): 180- 192. |
| 28 | Zhu YL, Wang LY, Wang JX, et al. Protective effects of paeoniflorin and albiflorin on chemotherapy-induced myelosuppression in mice[J]. Chin J Nat Med, 2016, 14 (8): 599- 606. |
| 29 | Luqman A, Hassan A, Ullah M, et al. Role of the intestinal microbiome and its therapeutic intervention in cardiovascular disorder[J]. Front Immunol, 2024, 15, 1321395. |
| 30 | Zhang Z, Wu G, Yang J, et al. Integrated network pharmacology, transcriptomics and metabolomics to explore the material basis and mechanism of Danggui-Baishao herb pair for treating hepatic fibrosis [J]. J Ethnopharmacol, 2025, 337(Pt 1): 118834. |
| [1] | Wei LIU, Wei ZHANG. Gut microbiota and colorectal cancer: advances from pathogenic mechanisms to therapeutic interventions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 937-947. |
| [2] | Jun WU, Yuwei SONG, Hongbiao LIANG, Juan FENG. Trimethylamine-N-oxide and vascular remodeling in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 774-781. |
| [3] | JIANG Jianxiang, DU Peiyan, LIU Yurong, LV Haihong. Correlation study between trimethylamine N-oxide and Hashimoto's thyroiditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1208-1214. |
| [4] | PENG Yuanyuan, CHEN Bilian. Research progress of the effect of TMAO on coronary heart disease and the efficacy of antiplatelet drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(5): 590-595. |
| [5] | ZHANG Qiang, ZHENG Huajun, LI Quan. Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480. |
| [6] | WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234. |
| [7] | ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314. |
| [8] | ZHAO Yangting, CHEN Chongyang, PAN Binjing, LV Xiaoyu, LIU Jingfang. Trimethylamine N-oxide: the potential target for osteoporosis treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1161-1167. |
| [9] | CHEN Qian, WANG Yafeng, DUO Delong, CHANG Ya'e, YAN Yingjun, DUAN Kunkun. Trigliptin succinate have an effect on gut microbiota of type 2 diabetic mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 15-24. |
| [10] | WANG Yaya, CHU Zixuan, YANG Junling, Olajide E. Olaleye, HE Rongrong, LI Muzi, CHENG Chen, LI Chuan. Potential health benefits of resveratrol: a pharmacokinetics-caused conundrum [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 931-954. |
| [11] | WU Rongrong, CHEN Zhiqiang, JIA Yifei, CHEN Hongqi, WANG Panpan, YAN Ru. Applications of BGUSs inhibition in tumor prevention and chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 964-974. |
| [12] | ZHENG Binjie, LIU Na, ZENG Xiangchang, HUANG Xinyi, CHEN Lulu, OU-YANG Dongsheng. Effects of gut microbiota on pharmacokinetics and its consideration in the evaluation of the consistency of quality and efficacy of generic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 662-671. |
| [13] | YAN Yu, LIU Kang, LIAN Wenwen, ZHANG Zhen, HE Jun. Research progress on roles of gut microbiota in cardiovascular disease and treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 829-834. |
| [14] | FANG Qing, OU-YANG Dongsheng. Trimethylamine N-oxide and inflammatory disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 318-326. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||